TY  - JOUR

T1  - Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable: an evidence review group perspective of a NICE single technology appraisal

JO  - PharmacoEconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/141166

PY  - 2019/09/01

AU  - Ren S

AU  - Squires H

AU  - Hock E

AU  - Kaltenthaler E

AU  - Rawdin A

AU  - Alifrangis C

ED  - 

DO  - DOI: 10.1007/s40273-018-0750-2

PB  - Springer Nature

VL  - 37

IS  - 9

SP  - 1073

EP  - 1080

Y2  - 2025/11/02

ER  -